Growing royalty anchors Neuren first ever dividend program
Filed with ASX · · 6 pages · English
Summary by 6ix AI
Neuren Pharmaceuticals Limited has announced its first-ever dividend program, which is supported by increasing royalty income from its product DAYBUE. The interim dividend for the first half of the year is fully franked and aims to enhance total shareholder returns. In the same period, Neuren reported significant growth in royalty income and a profit after tax, alongside a strong cash position.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neuren Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Neuren Pharmaceuticals
- European Commission grants marketing authorisation for DAYBU
- Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded
- DAYBU recommended for approval in the European Union
- Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025
- DAYBUE STIX now broadly available in US for Rett syndrome
Later from Neuren Pharmaceuticals
- Trofinetide US patent protections extended to March 2041
- FDA grants Orphan Drug Designation for NNZ-2591 to treat HIE
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals